Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment

Frontiers in Drug Delivery, Journal Year: 2024, Volume and Issue: 4

Published: Feb. 1, 2024

Ovarian cancers are a complex and heterogenic group of malignancies that difficult to detect, diagnose treat. Fortunately, considerable knowledge ovarian cancer specific biomarkers has been generated, is pertinent the development novel theranostic platforms by combining therapies diagnostics. Genomic proteomic data invaluable in providing critical biomolecular targets for approaches. Exploitation wealth biomarker research conducted offers viable as beacons detection, diagnosis, therapeutic targeting. These markers can be used theranostics, treatment strategy combines therapy diagnostics common nuclear medicine, where radionuclides both diagnosis treatment. The theranostics taken substantial focus recent years battle against cancer. Yet date only one technology emerged clinical practice. However, given field poised see emergence revolutionary disease monitoring outcomes through their incorporation into strategies. future set enable precise targeted treatment, vigilant monitoring. This review aims assess status diagnostic tools practice, development, or pre-clinical highlighting newly emerging applications.

Language: Английский

---

An Ultrasound‐Responsive and In Situ Gelling Hydrogel Nanocomposite for Boosting Anti PD‐L1 Immunotherapy via Remodeling Aberrant ECM of Post‐Surgical Residual Cancer

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(44)

Published: May 17, 2024

Abstract Tumor recurrence and metastasis following surgery remain formidable challenges. Although that is a crucial factor in determining efficacy of postoperative immune treatment, the impact on tumor microenvironment (TME) still understudied specific treatment options for residual cancer are unsatisfactory. Here, it verified abnormal extracellular matrix (ECM) postsurgical results deteriorative hypoxia, immunosuppression, hypo‐perfusion, which further promotes invasion may hinder checkpoint blockades (ICB). To adaptively potentiate ICB therapy this context, an ultrasound‐responsive, visualized, situ gelling hydrogel nanocomposite (TPP ALG) prepared through combining phase change nanoparticles alginate solution normalizing ECM with controllable delivery tranilast. After injection ions situ, TPP ALG enables ultrasound visualized responsive local long‐term retention, capable ECM, improving remodeling immunosuppressive microenvironment, enhancing permeation boosting immunotherapy. Ultimately, synergistic approach effectively inhibit lung post operation, thereby delaying survival. Therefore, based clinical drug biocompatible materials, simple‐synthesized holds great application prospects inhibiting metastasis.

Language: Английский

---

Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(6), P. 189020 - 189020

Published: Nov. 1, 2023

Language: Английский

---

Dual‐Functional Nanodroplet for Tumor Vasculature Ultrasound Imaging and Tumor Immunosuppressive Microenvironment Remodeling

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: unknown

Published: July 19, 2024

Abstract Accurately evaluating tumor neoangiogenesis and conducting precise interventions toward an immune‐favorable microenvironment are of significant clinical importance. In this study, a novel nanodroplet termed as the nanodroplet‐based ultrasound contrast agent therapeutic (NDs UCA/Tx ) is designed for imaging neoangiogenesis. Briefly, NDs shell constructed from engineered CMs containing antigen, vascular endothelial growth factor receptor 1 (VEGFR1) extracellular domain 2–3, CD93 ligand multimerin 2. The core composed perfluorohexane immune adjuvant R848. After injection, found to be enriched in vasculature with high expression CD93. When triggered by ultrasound, underwent acoustic droplet vaporization generated enhanced signal. Some microbubbles exploded resultant debris (with antigen R848) together adsorbed VEGF taken up nearby cells. This cleared local normalization, also served vaccine activate response. Using syngeneic mouse model, satisfactory performance activation confirmed. Thus, multifunctional successfully developed molecular remodeling microenvironment.

Language: Английский

---

Bidirectional regulation of reactive oxygen species for radiosensitization in nasopharyngeal carcinoma

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 8, 2025

Radiotherapy (RT) is the primary treatment modality for nasopharyngeal carcinoma (NPC). However, tumor microenvironment (TME)-induced radioresistance often compromises its therapeutic efficacy. Herein, we propose an innovative bidirectional radiosensitization strategy NPC. Specifically, have encapsulated metformin (Met) and copper sulfide nanoparticles (CuS NPs) within injectable DNA supramolecular hydrogels (DSH) to create a novel radiosensitizer, Met-CuS@DSH. This radiosensitizer not only effectively reverses hypoxia promote reactive oxygen species (ROS) generation but also significantly inhibits glutathione (GSH)-mediated ROS scavenging, thereby achieving by enhancing production suppressing scavenging. improves effect of NPC while reducing RT dose (3 Gy in total), which provides promising approach overcoming caused TME.

Language: Английский

---

Global trends and research hotspots in nanodrug delivery systems for breast cancer therapy: a bibliometric analysis (2013–2023)

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 6, 2025

Nanomedicine offers fresh approaches for breast cancer treatment, countering traditional limitations. The nanodrug delivery system's precision and biocompatibility hold promise, yet integration hurdles remain. This study reviews nano systems in therapy from 2013 to 2023, guiding future research directions. In this study, we conducted a comprehensive search on Web of Science database (Guilin Medical University purchase edition) downloaded literature related the field published between 2023. We analyzed these publications using R software, VOSviewer, CiteSpace software. reviewed 2632 documents, showing steady publication increase peaking at 408 2022. China, USA, India, Iran were prominent publishing. Chinese Academy Sciences Tabriz key collaboration centers. Notably, Journal Controlled Release Biomaterials ranked among top 10 journals citations, establishing their representation. Key terms like "breast cancer," "nanoparticles," "drug delivery," "in-vitro," "delivery" widely used. Research focused optimizing drug targeting, utilizing tumor microenvironment delivery, improving efficiency. system, as an innovative approach, numerous advantages has garnered global attention researchers. provides analysis status hotspots within realm therapy, offering valuable insights domain.

Language: Английский

---

Advanced Nanobiomaterial-Mediated Radio-Immunotherapy in Malignant Cancer

Published: Jan. 1, 2025

Language: Английский

---

Role and mechanisms of exercise therapy in enhancing drug treatment for glioma: a review

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 30, 2025

Gliomas, particularly glioblastoma (GBM), are among the most aggressive and challenging brain tumors to treat. Although current therapies such as chemotherapy, radiotherapy, targeted treatments have extended patient survival some extent, their efficacy remains limited is often accompanied by severe side effects. In recent years, exercise therapy has gained increasing attention an adjunctive treatment in clinical research settings. Exercise not only improves patients’ physical function cognitive abilities but may also enhance of conventional drug modulating immune system, suppressing inflammatory responses, improving blood-brain barrier permeability. This review summarizes potential mechanisms glioma treatment, including enhancing surveillance through activation natural killer (NK) cells T cells, penetration function. Additionally, studies suggest that can synergize with chemotherapy immunotherapy, outcomes while reducing drug-related application patients still exploratory phase, existing evidence indicates its significant value approach, become a new standard future.

Language: Английский

---

Angiogenesis in rheumatoid Arthritis: Pathological characterization, pathogenic mechanisms, and nano-targeted therapeutic strategies

Bioactive Materials, Journal Year: 2025, Volume and Issue: 50, P. 603 - 639

Published: May 2, 2025

Language: Английский

---

Nanotherapeutic Formulations for the Delivery of Cancer Antiangiogenics

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Antiangiogenic medications for cancer treatment have generally failed in showing substantial benefits terms of prolonging life on their own; effects are noticeable only when combined with chemotherapy. Moreover, treatments based prolonged antiangiogenics administration demonstrated to be ineffective stopping tumor progression. In this scenario, nanotherapeutics can address certain issues linked existing antiangiogenic treatments. More specifically, they provide the ability target tumor's blood vessels enhance drug accumulation and manage release, ultimately decreasing undesired side effects. Additionally, enable multiple angiogenesis inhibitors at same time as Key reports field include design polymeric nanoparticles, inorganic vesicles, hydrogels loading substances like endostatin interleukin-12. Furthermore, nanoformulations been proposed efficiently control relevant pro-angiogenic pathways such VEGF, Tie2/Angiopoietin-1, HIF-1α/HIF-2α, TGF-β, providing powerful approaches block growth metastasis. article, we outline a selection that developed past ten years.

Language: Английский

---